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Metabolic homeostasis in the organism is assured both by the nervous system and by hormones.
Among a plethora of hormones regulating metabolism, serotonin presents a number of unique fea-
tures. Unlike classical hormones serotonin is produced in different anatomical locations. In brain it
acts as a neurotransmitter and in the periphery it can act as a hormone, auto- and/or paracrine fac-
tor, or intracellular signaling molecule. Serotonin does not cross the blood–brain barrier; therefore
the two major pools of this bioamine remain separated. Although 95% of serotonin is produced in
the periphery, its functions have been ignored until recently. Here we review the impact of the
peripheral serotonin on the regulation of function of the organs involved in glucose and lipid
homeostasis.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Serotonin (5-hydroxytryptamine, 5-HT) is a bioamine derived
from the amino acid tryptophan. In serotonin producing cells, tryp-
tophan is hydroxylated by the rate limiting enzyme tryptophan
hydroxylase (TPH) and subsequently decarboxylated by aromatic
acid decarboxylase (AADC) [1]. Serotonin was found in a variety
of organisms including fungi, plants and invertebrates [2–4]. In
vertebrates, two major pools of serotonin can be distinguished:
the brain serotonin, synthesized mainly in the brainstem, and the
peripheral serotonin. Synthesis of serotonin in both locations relies
on the enzyme tryptophan hydroxylase, which is encoded by two
different genes, Tryptophan hydroxylase 1 (Tph1) and Tryptophan
hydroxylase 2 (Tph2) expressed in the periphery and in the brain,
respectively. Serotonin does not cross the blood–brain barrier,
and thus each pool of this molecule has its distinct functions [5]
(Fig. 1). In the brain serotonin serves as a neurotransmitter. It reg-
ulates multiple physiological aspects, including: behavior, learn-
ing, and appetite and glucose homeostasis, which have been
extensively reviewed [6–8]. However, the brain-derived serotonin
accounts only for around 5% of total body serotonin [5]. The
remaining 95% of serotonin is produced in the peripheral organsand it became clear in recent years that it regulates function of
multiple aspects of physiology.
In the periphery the vast majority of serotonin is produced by
enterochromafﬁn cells of the gut. The Gut-derived serotonin
(GDS) can act locally in the gastrointestinal (GI) tract or it can enter
into the blood circulation. In the blood, serotonin is taken up and
stored by platelets and is released during blood coagulation.
Approximately only 2% of the blood serotonin is free in the ﬂuids
and can act directly as a hormone [5] (Fig. 2). Interestingly, multi-
ple other peripheral cell types including pancreatic b cells [9,10],
adipocytes [11], and osteoclasts [12] can produce serotonin.
Thus, serotonin availability in the peripheral tissues is determined
by both the local production and by concentration ‘‘of the free hor-
mone’’ in the blood.
Serotonin-mediated signaling in target cells is further
complicated by the existence of at least fourteen different recep-
tors for this hormone. Seven classes of serotonin receptors
(5-hydroxytryptamine receptors – Htrs) have been identiﬁed so
far (Htr1 to Htr7). Among them, Htr3 is the only ligand-gated ion
channel receptor for serotonin. All other serotonin receptors
belong to the G-protein coupled receptor superfamily. However,
different classes of Htrs are coupled to a variety of G-proteins
and evoke distinct intracellular signaling cascades [5,13] (Fig. 1).
Moreover, extracellular serotonin might be taken up by various cell
types through serotonin transporters (SERT), subsequently metab-
olized, and degraded. Importantly, intracellular metabolites of
serotonin might also act as signaling molecules [14].
Fig. 1. Serotonin synthesis and signaling in the brain and in periphery. The amino acid tryptophan is hydroxylated by the rate-limiting enzyme tryptophan hydroxylase (TPH)
and then subsequently decarboxylated by aromatic acid decarboxylase (AADC). In vertebrates two forms of TPH, encoded by two different genes, can be distinguished: TPH1,
which is expressed in the periphery, and TPH2 expressed mainly in the brain. Since serotonin cannot cross the blood–brain barrier this molecule exhibits distinct functions in
both locations. Serotonin exerts its effects in target cells through at least fourteen receptors. Thirteen of them belong to the G-protein coupled receptors (GPCR) superfamily.
Among these, four subfamilies are distinguished, based on their coupling to different G-proteins and utilization of different secondary messengers. Htr3 is the only ligand-
gated ion channel receptor for serotonin. In the ﬁgure: cAMP – cyclic adenosine monophosphate, cADPR – cyclic adenosine diphosphate ribose, IP3 – inositol trisphosphate.
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para- and endocrine actions of serotonin produced in the periphery
on the regulation of glucose and lipid homeostasis.
2. Serotonin regulates pancreatic b cell function in an autocrine
manner
Insulin producing pancreatic b cells are the main cell type reg-
ulating glucose and lipid homeostasis in the body. Generally, insu-
lin promotes glucose uptake in the peripheral cells, synthesis of
glycogen and proteins, as well as de novo lipogenesis. At the same
time insulin suppresses hepatic glucose production (gluconeogen-
esis) and the release of triglycerides stored in adipose tissue (lipol-
ysis). Since insulin regulates key aspects of nutrient homeostasis,
its production and secretion from pancreatic b cells need to be
tightly regulated to meet different physiological and environmen-
tal challenges. Therefore, insulin production, secretion, and pancre-
atic b cells mass are controlled not only by nutrients (mainly
glucose) levels but also by the nervous system and hormones
[15,16].
Pancreatic b cells share common developmental features with
serotonin producing neurons in the hindbrain [17]. Indeed, a num-
ber of studies conﬁrmed that enzymes required for serotonin syn-
thesis and secretion are also expressed in b cells. Interestingly, b
cells express both brain- and peripheral-speciﬁc rate-limitingenzymes for serotonin synthesis (Tph1 and Tph2) [9,10,17–19].
Therefore, both locally produced serotonin and serotonin present
in the circulation might inﬂuence the function of pancreatic b cells.
Tph1-deﬁcient mice (Tph1/) are glucose intolerant and
develop mild form of diabetes [10,20] due to impaired insulin
secretion from b cells [10]. Paulmann and colleagues demonstrated
that the intracellular concentration of serotonin correlates posi-
tively with insulin secretion rate. Their experiments performed
on the rat insulinoma cell line INS1 suggest also that extracellular
serotonin might suppress insulin secretion [10]. Accordingly, iso-
lated Tph1-deﬁcient b cells display impairment in insulin granule
exocytosis. The same study showed that intracellular serotonin
covalently couples speciﬁc small GTPases (Rab3a and Rab27a) to
activate them, which in turn promotes glucose-mediated insulin
granule exocytosis. Under normal conditions, pancreatic islet mor-
phology, number and size are unaffected in Tph1/ mice [10].
Taken together this study suggests that serotonin promotes insulin
granule exocytosis in b cells in an autocrine, receptor independent
manner. Of note, reduction of serotonin levels exclusively in the
circulation (by deleting Tph1 in the enterochromafﬁn cells of the
gut) does not inﬂuence insulin levels in mice [20]. Accordingly,
pancreatic b cell-speciﬁc deletion of Tph1 resulted in decreased
insulin secretion, circulating insulin levels and impaired tolerance
to glucose in diabetic mice [21]. The same authors showed that
deletion of ligand-gated ion channel serotonin receptor Htr3a in
Fig. 2. Multifaceted regulation of metabolism by peripheral serotonin. The majority of serotonin is produced by enterochromafﬁn cells of the gut (GDS), where it can act
locally or can enter the general circulation. In the blood serotonin is taken up and stored by platelets. Only about 2% of blood serotonin is free in the plasma and can directly
act as a hormone. GDS signals in white adipocytes mainly through the Htr2b receptor. It promotes lipolysis and therefore secretion of free fatty acids (FFAs) and glycerol.
Serotonin might also be produced by adipocytes and regulate lipogenesis via Htr2a and Htr2b receptors. In brown adipocytes serotonin suppresses adaptive thermogenesis
and glucose uptake by acting through Htr3a. In liver, GDS promotes gluconeogenesis and inhibits glucose uptake by acting through Htr2b receptor. Serotonin can also be
produced by pancreatic b cells. Locally produced serotonin promotes insulin secretion from pancreatic b cells by acting through the Htr3a receptor or by acting on
intracellular effector proteins directly. Moreover it promotes expansion of pancreatic b cells during pregnancy by signaling through the Htr2b receptor. Peripheral serotonin
might also promote glycolysis in skeletal muscles and modulate inﬂammatory cytokine production, which might affect peripheral insulin sensitivity.
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cose intolerance, but only in diabetic mice [21].
Altogether, these ﬁndings suggest that only locally produced
serotonin promotes pancreatic b cells function in a
receptor-dependent (Htr3a) and independent manner.
Pancreatic b cell mass and insulin secretion increase at the time
of elevated demand for insulin in the periphery. Such conditions
occur during pregnancy. Expression of Tph1, Tph2, and the produc-
tion of serotonin in b cells are markedly elevated as early as 6 days
post conception [9]. Indeed, serotonin signaling during pregnancy
is required for adaptive proliferation of b cells. Serotonin induces
b cell proliferation by acting via the Gaq-linked Htr2b receptor.
Consistently, Htr2b-deﬁcient mice develop gestational diabetes[9]. During pregnancy not only elevation of pancreatic b cells mass
is observed, but also their increased responsiveness to glucose. A
recent study of Ohara-Imaizumi and colleagues demonstrated that
serotonin promotes also this aspect of b cells adaptation to preg-
nancy [19]. They showed that serotonin acts via the Htr3a
Na+-K+-selective ion channel receptor. Htr3a stimulation activates
an inward current and depolarizes the b cell membrane, causing
a reduction of its potential and thus decreasing the threshold for
glucose to induce voltage-dependent Ca2+ entry to promote insulin
exocytosis [19]. As a consequence of decreased insulin secretion,
mice deﬁcient for Htr3a receptor develop glucose intolerance dur-
ing pregnancy [19]. Although deletion of Htr3a receptor in b cells
attenuates their adaptation to increased insulin demand during
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deletion does not affect insulin levels or glucose tolerance in
healthy mice [19,21].
Intriguingly, serotonin might also contribute to the develop-
ment of pancreatic b cell dysfunction during conditions of severe
obesity and peripheral insulin resistance. In pancreatic islets iso-
lated from diabetic mice, the expression of serotonin receptor
Htr2c is elevated. This overexpression of Htr2c inhibits insulin
secretion in diabetic subjects [22].
Taken together, locally produced serotonin acts on pancreatic b
cells to promote insulin secretion, adaptation to pregnancy, and
peripheral insulin resistance. However, serotonin might also pro-
mote failure of b cells during diabetes, but the precise molecular
mechanisms remain to be investigated.
3. Gut-derived serotonin promotes gluconeogenesis and
suppresses glucose uptake by hepatocytes
Liver plays a pivotal role in the regulation of blood glucose
levels. When nutrients are available in excess, hepatocytes absorb
glucose and store it in form of the polysaccharide glycogen. During
food deprivation liver initially maintains glucose levels in the cir-
culation by degrading glycogen and during prolonged fasting by
de novo glucose synthesis (gluconeogenesis) from glycerol and
amino acids. Liver is also the major organ controlling blood triglyc-
erides and cholesterol levels. Insulin and glucagon are the principle
hormones controlling the metabolism of hepatocytes [23].
Several lines of evidence indicate that peripheral serotonin also
acts directly on hepatocytes. Peripheral serotonin promotes liver
regeneration after injury by acting via the Htr2b receptor on hep-
atocytes to promote their proliferation [24]. Moreover, activation
of Htr2b receptor promotes proliferation and inhibits autophagy
of hepatocellular cancer cells [25].
A number of in vitro and expression studies indicate that
peripheral serotonin might also regulate hepatic glucose and lipid
metabolism. Administration of serotonin in rats results in
increased expression of phosphoenolpyruvate carboxykinase
(PEPCK) in liver, suggesting that serotonin promotes hepatic gluco-
neogenesis [26]. On the other hand, stimulation of mouse hepatic
tissue with serotonin results in increased activity of phosphofruc-
tokinase (PFK), indicating that serotonin rather promotes glycoly-
sis in hepatocytes [27]. In addition, in vitro experiments suggest
that depending on its concentration serotonin can either stimulate
or inhibit glycogen synthesis [28]. We utilized mice deﬁcient for
Gut-derived serotonin (GDS) (Tph1 gut-speciﬁc knockout mice) to
study its speciﬁc effect on the regulation of hepatic glucose han-
dling. Our results showed that mice deﬁcient for GDS present bet-
ter peripheral glucose disposal and reduced hepatic glucose
production. Importantly, mice deﬁcient for Htr2b in hepatocytes
exhibited the same phenotype, suggesting that serotonin regulates
hepatic glucose metabolism mainly through this receptor.
Furthermore, serotonin promoted gluconeogenesis by increasing
the activity of two rate-limiting enzymes required for this process,
glucose 6-phosphatase (G6Pase) and fructose 1,6-bisphosphatese
(FBPase). At the same time, deletion of Htr2b receptor speciﬁcally
in hepatocytes promoted hepatic glucose uptake by preventing
serotonin-evoked degradation of glucose transporter 2 (Glut2)
[20]. Yet, another study performed in 42 h-fasted conscious dogs
indicated that administration of serotonin in animals previously
infused with insulin, glucagon and somatostatin hyperinsuline
mic–euglycemic clamp experiment resulted in a net increase of
hepatic glucose uptake [29]. In the work of Watanabe et al., how-
ever, serotonin injection in fasted mice resulted in increased glu-
cose levels in the circulation, and did not signiﬁcantly affect
hepatic uptake of 2-deoxy-glucose [30]. The same study reportedthat serotonin might also decrease triglycerides and cholesterol
levels in the circulation, indicating that this hormone could also
be involved in regulation of hepatic lipid handling [30].
Taken together, genetic studies indicate that GDS signaling in
hepatocytes promotes gluconeogenesis and suppresses hepatic
glucose uptake. However, experiments based on single shot injec-
tion of serotonin revealed that this bioamine might exert different
effects on hepatic glucose metabolism depending on the species, as
well as the hormonal and physiological context.
4. Serotonin – a new hormone regulating adipose tissue
functions
Adipose tissue or fat is specialized in the storage of large quan-
tities of nutrients. Two main functionally different types of fat
depots have been distinguished until recently, white and brown
adipose tissue [31]. Lately, another functionally relevant subtype
of fat tissue was identiﬁed, named beige or bright adipose tissue
[32]. White adipose tissue acts as a main storage of energy in the
organism. During the fed stage, adipocytes absorb the excess of
lipids and sugars to protect other peripheral organs from their
toxic effects. Adipocytes respond to the shortage of nutrients by
inducing lipolysis, a process leading to mobilization and release
of free fatty acids (FFAs) and glycerol through catabolism of stored
triglycerides [33]. Brown and beige adipocytes in addition to their
capacity for lipid storage are also able to dissipate energy to pro-
duce heat and to maintain optimal body temperature [32]. In addi-
tion, all types of adipocytes secrete multiple hormones
(adipokines), which regulate the metabolism of other organs
[34]. Importantly, defective clearance of nutrients and increased
lipid output by adipocytes, as well as decreased thermogenesis
and perturbations in adipokine production, contribute to the
development of metabolic diseases such as obesity and type 2 dia-
betes (T2D) [35].
First observations indicating that peripheral serotonin might be
involved in the regulation of adipocyte function were made as
early as in 1967. Injection of serotonin into healthy humans
increased free fatty acid (FFA) and glycerol levels in the blood, indi-
cating induction of lipolysis. Moreover, serotonin stimulation of
human subcutaneous white adipose tissue from biopsies and rat
epididymal white adipose tissue explants increased glycerol
release [36]. However, more recently it has been reported that sin-
gle shot injection of serotonin in fasted mice (which increased its
levels in plasma over 70 times) resulted in reduced FFAs levels
[30]. This suggests that high increase of blood serotonin levels
might have opposite effects than moderate elevation of this hor-
mone concentration. In our study, we demonstrated that GDS
levels are induced in blood upon food deprivation. Using mice deﬁ-
cient for Tph1 in the GI tract we showed that GDS is required for
maximal activation of lipolysis during fasting. Further analyses
revealed that serotonin stimulates lipolysis in white adipocytes
by acting on its receptor Htr2b to activate hormone sensitive lipase
(HSL). Consistent with this observation, adipocyte-speciﬁc ablation
of Htr2b resulted in reduction of FFAs and glycerol levels in the
blood of fasted mice [20]. Additionally, stimulation of Htr2b recep-
tor by GDS might also suppress lipogenesis, as another research
group showed that ablation of Htr2b signaling during differentia-
tion of adipocytes in vitro results in triglyceride accumulation in
these cells [37]. Moreover, serotonin stimulation of white adipo-
cytes results in impaired insulin action, degradation of insulin
receptor substrate-1 (IRS-1), and reduced glucose uptake [38].
Although Htr2b seems to be required for proper lipid handling by
white adipocytes, Htr2a and Htr2c receptors are also expressed
in these cells. Moreover, adipocytes seem to express Tph1 and
serotonin transporter (SERT), and therefore the function of these
1732 R. El-Merahbi et al. / FEBS Letters 589 (2015) 1728–1734cells might be also regulated by serotonin in an autocrine manner
[11]. In fact, deletion of Tph1 in the pre-adipocyte cell line 3T3-L1
resulted in a defect of differentiation of these cells to adipocytes,
and in decreased expression of a key transcription factor required
for adipocyte differentiation, Peroxisome proliferator-activated
receptor gamma (PPARc) [39,40]. Incubation of Tph1-deﬁcient
3T3-L1 cells with serotonin rescued the defect in differentiation
of these cells into adipocytes, suggesting autocrine action of sero-
tonin produced by pre-adipocytes. Locally produced serotonin pro-
motes differentiation of adipocytes at least partially by acting
through Htr2a and Htr2c receptors, as revealed by their pharmaco-
logical inhibition. Yet, serotonin might promote differentiation of
adipocytes in a receptor-independent manner. Recent studies
revealed that SERT-mediated uptake and subsequent degradation
of serotonin in pre-adipocytes results in the generation of
5-hydroxy-indole acetate and 5-methoxy indole acetate, which
can act as PPARc agonists to promote differentiation of adipocytes
[14]. Additionally, signals transmitted via Htr2a receptor suppress
expression of adiponectin [41], an adipokine which promotes
peripheral insulin sensitivity [31] but at the same time promote
lipogenesis in these cells [42].
Recent studies revealed that serotonin also acts on brown and
beige adipocytes. In obese mice local serotonin concentration in
brown adipose tissue (BAT) is markedly elevated [43]. Serotonin
stimulation of brown adipocytes blocks catecholamine (b
adrenergic)-induced signaling and consequently expression of the
key factor promoting thermogenesis in BAT, uncoupling protein 1
(Ucp-1). This leads to a reduction of thermogenesis and decreased
dissipation of energy by brown adipocytes [43]. Consistent with
this, mice with global deletion of Tph1 (Tph1/ mice) fed a high
fat diet present increased thermogenesis and energy expenditure,
and are resistant to obesity [43]. Of note, as in the case of white
adipocytes, serotonin stimulation of brown adipocytes blocks glu-
cose uptake [43]. Another research group discovered that serotonin
produced locally by adipocytes is responsible for suppression of
adaptive thermogenesis in brown and beige adipocytes. In fact,
deletion of Tph1 only in adipocytes results in increased Ucp-1
expression and energy expenditure, and resistance to
diet-induced obesity. Moreover the same research group showed
that serotonin acts on brown/beige adipocytes via the Htr3a recep-
tor [42].
In conclusion, serotonin signaling in white adipocytes promotes
lipolysis and insulin resistance, and suppresses glucose uptake and
adiponectin production. Moreover, serotonin signaling via Htr2a
might promote, while stimulation of Htr2b receptor might sup-
press lipogenesis. Additionally, serotonin produced locally by adi-
pocytes acts on brown adipocytes to suppress thermogenesis.
5. Action of serotonin on immune cells – possible involvement
in regulation of metabolism
While peripheral serotonin directly regulates metabolism of
pancreatic b cells, liver and adipocytes, it also acts on a number
of immune cell types, which can inﬂuence the function of major
organs regulating glucose and lipid homeostasis. It is well estab-
lished that chronic, low grade inﬂammation in obese subjects,
associated with elevated levels of pro-inﬂammatory cytokines,
contributes to peripheral insulin resistance and pancreatic b cell
failure [44].
Peripheral serotonin acts on several inﬂammatory cell types. It
promotes the recruitment of neutrophils to the site of inﬂamma-
tion [45]. Studies using Tph1-deﬁcient mice showed that periph-
eral serotonin exacerbates development of inﬂammatory
diseases, e.g., colitis, by recruiting macrophages and promoting
secretion of pro-inﬂammatory cytokines [46]. On the other hand,experiments on isolated macrophages suggest that peripheral
serotonin might rather inhibit lipopolysaccharide (LPS)-induced
secretion of pro-inﬂammatory cytokines [47]. However, the impact
of peripheral serotonin action in macrophages and other immune
cells on regulation of glucose and lipid metabolism remains poorly
understood and awaits further studies in future.
6. Serotonin functions in other peripheral organs
Available in vitro experiments suggest that peripheral serotonin
might also inﬂuence glucose homeostasis in skeletal muscle.
Serotonin receptor Htr2a has been found in both white and red
muscle ﬁbers [48]. Other experiments indicate that serotonin stim-
ulates skeletal muscle PFK activity and thus augments skeletal
muscle glucose consumption through stimulation of glycolysis
[49,50]. However, in vivo genetic analysis of serotonin signaling
in muscle is missing at this point.
The majority of serotonin is produced in the GI tract by ente-
rochromafﬁn cells. However, only a small portion of serotonin
enters the general circulation [5]. Therefore, it is reasonable to
hypothesize that serotonin also acts locally in the GI tract.
Indeed, GDS mediates inﬂammatory processes in the intestines,
which was reviewed in detailed previously [51]. It was also sug-
gested that serotonin regulates gut motility [51]. However, a recent
study showed that mice deﬁcient for Tph1 display normal total
transit time of food through the GI tract [52]. Consistently, we
did not observe any changes in the body weight in mice deﬁcient
for Tph1 in the gut. Also, these animals presented normal food
intake and total energy expenditure [20]. Thus, GDS action in the
GI tract may indirectly inﬂuence metabolic homeostasis.
7. Targeting synthesis of peripheral serotonin for treatment of
metabolic disorders
Inappropriate regulation of glucose and lipids metabolism can
lead to the development of multiple metabolic diseases including
diabetes. Hyperglycemia and hyperlipidemia are the hallmarks of
diabetes mellitus, which results from peripheral insulin resistance
in combination with an inability of pancreatic b cells to produce
insulin in sufﬁcient amounts.
Serotonin reuptake inhibitors, which increase the serotonin
pool in the central nervous system, are commonly used for treat-
ment of mental disorders [6]. However, the therapeutic potential
of targeting the serotonin system in the periphery has not been
fully explored to date. Because serotonin does not cross the
blood–brain barrier and the majority of serotonin producing cells
in the periphery are located in the GI tract, targeting gut-derived
serotonin synthesis by orally given compounds might be an attrac-
tive therapeutic strategy. Metabolomic analyzes of serum of obese,
insulin-resistant mice revealed a greater than 7-fold increase in the
concentration of serotonin compared to that in non-obese,
non-insulin-resistant control animals [53]. Moreover, given that a
reduction of serotonin synthesis in the periphery results in
decreased lipolysis and hepatic gluconeogenesis in combination
with increased hepatic glucose uptake [20], and at the same time
promotes energy dissipation by brown adipocytes [42,43], one
can predict that inhibition of GDS production might attenuate
the course of type 2 diabetes.
In fact, Tph1 inhibitors that decrease circulating serotonin
levels without affecting brain serotonin are available and have
been tested in animal models [54]. In our study, we have used
the Tph1 inhibitor LP533401 to treat symptoms of diabetes in
mice. A daily oral dose of LP533401 improved peripheral insulin
sensitivity and glucose tolerance, and decreased hyperglycemia
and hyperlipidemia in diabetic mice (in which diabetes was
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serotonin synthesis in the periphery might be an attractive strat-
egy to treat type 2 diabetes also in humans.
Although serotonin is a crucial factor sustaining pancreatic b
cell function [9,10], oral dosage of Tph1 inhibitor did not affect
peripheral insulin levels. This result might suggest that the dose
of LP533401 inhibitor used in our experiments was sufﬁcient to
suppress serotonin synthesis in enterochromafﬁn cells of the gut,
but not in pancreatic b cells.
Recently Crane and colleagues also utilized the LP533401 inhi-
bitor for treatment of obesity-induced diabetes in mice. They per-
formed daily intraperitoneal injections of this inhibitor, rather than
oral dosage. LP533401 inhibitor distributed in mice in this way also
reduced hyperglycemia and peripheral insulin resistance, and
additionally increased energy expenditure of the mice and attenu-
ated obesity [43]. Similar results were also obtained by another
research group [42].
Since type 2 diabetes is usually associated with increased risk of
developing other metabolic disorders such as atherosclerosis or
fatty liver disease, it would be crucial to test the impact of Tph1
inhibitors on the development of these diseases. Indeed, the inhibi-
tion of GDS synthesis has been patented as a method of preventing
and treating hyperlipidemia and atherosclerosis [55]. Moreover,
multiple studies suggest that inhibitors of GDS synthesis might
be useful in the treatment of inﬂammatory disorders [45,46,51],
as well as low bone mass disease osteoporosis [56]. Therefore,
Tph1 inhibitors might serve as a multi-target drug in future.
8. Conclusions and outlook
Although the impact of serotonin produced in the central ner-
vous system on the regulation of behavior and physiology has been
in the center of scientiﬁc interest for decades, until recently
peripheral serotonin has been ignored. Lately it became clear that
the serotonin system in the periphery regulates multiple physio-
logical aspects independently of the brain-derived serotonin. In
particular, peripheral serotonin plays a pivotal function in the reg-
ulation of glucose and lipid homeostasis by acting on different
organs and cell types. Serotonin produced in pancreatic b cells pro-
motes insulin secretion and during pregnancy also b cell prolifera-
tion [9,10,19,21,22]. Serotonin produced in intestine acts on the
liver to promote gluconeogenesis and to suppress hepatic glucose
uptake [20], and on white adipocytes to promote lipolysis [20]
and to suppress glucose uptake, adiponectin production and insu-
lin action [38,41]. Serotonin produced directly in the adipocytes
suppresses thermogenesis and glucose uptake in another func-
tional type of fat – brown adipose tissue [42,43]. Moreover, sero-
tonin might act directly on muscle to promote glycolysis [49,50],
and it promotes cytokine production in macrophages [46] (Fig. 2).
However, serotonin signaling in the periphery presents enor-
mous complexity due to the multiple sites of production of this
molecule, its capacity to act as an auto-, para- and endocrine factor,
and the existence of at least 14 serotonin receptors. This plethora
of actions of peripheral serotonin is being recently unraveled by
studies utilizing cell speciﬁc deletion approaches to target speciﬁc
receptors or rate limiting enzymes for serotonin synthesis. These
efforts are greatly stimulated by the fact that targeting of the com-
ponents of peripheral serotonin synthesis and signaling presents
great therapeutic potential in inﬂammatory and bone degenerative
diseases and for different forms of diabetes.
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